Slade Pharmacy Services has entered into agreements with Fresenius Kabi to purchase its Oncology Compounding Business in Australia. This includes all the TGA-licenced compounding facilities in Queensland, NSW and Victoria. Slade says it intends to retain the staff currently employed at the facilities. Slade currently operates a TGA-licenced manufacturing facility in Victoria and services both
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.